Tissue Genesis Inc. began clinical trials for a peripheral vascular disease (PVD) treatment composed of adipose-derived adult stem cell-coated vascular grafts. Adipose is more commonly know as fat, a tissue that the company believes has high-output regenerative medicine potential.
The Honolulu-based Tissue Genesis is the first to initiate an FDA-approved trial using the patient’s own fat-derived adult stem cells (ASCs) prepared at the point-of-care, according the company company.
Scientists have been working on way to coat the inside of the synthetic grafts used to treat PVD so that the devices more closely resemble native vessels and increase long-term graft survival, the company said. ASCs can be obtained with a liposuction procedure that Tissue Genesis called "quick and simple."
"Based on previous studies, the potential of ASCs to increase the patency and life of the graft is tremendous," chief science officer Dr. Stuart Williams said in prepared remarks.
Here’s a roundup of recent clinical trial and scientific study news:
- Study: Exergen temporal artery thermometry accurate on newborns
Measuring the body temperatures of newborns with temporal artery thermometry (forehead scanning) provides readings comparable to results obtained by axillary (under arm) thermometry, the clinically recommended method for this patient population, but causes less discomfort, according to a new study reported in Advances in Neonatal Care.
- Study finds lung nodules easier to find with rib and clavicle suppressing software
Radiologists using visualization software significantly increased their detection of lung cancers and benign nodules. The purpose of the Radiology-published study was to demonstrate possible superiority in the performance of a radiologist who is tasked with detecting actionable nodules and aided by the bone suppression and soft-tissue visualization algorithm of a new software program that produces a modified image by suppressing the ribs and clavicles, filtering noise, and equalizing the contrast in the area of the lungs.
- ConvaTec touts study results on wound dressing containing silver
ConvaTec, a developer and marketer of innovative medical technologies for community and hospital care, announced new in vitro study results showing that a wound dressing containing ionic silver is able to kill several strains of highly-resistant bacteria, commonly referred to as ‘superbugs.’ The study showed that bacteria found beneath the dressing died within 48 hours.(1) The study results were presented at the 24th Annual Symposium on Advanced Wound Care and Wound Healing Society (SAWC/WHS) in Dallas, Texas.
- Pico-Tesla touts results from pilot study of Magneceutical therapy for fibromyalgia
Pico-Tesla announced that a randomized, double-blind, placebo-controlled pilot study of 13 patients who have fibromyalgia suggests promise for its Therapy designed to improve symptoms of Pain and Sleep in this patient population. The pilot study sought to determine whether the application of magnetic fields generated by Pico-Tesla’s patented Resonator system can be effective as an adjunctive therapy to oral medications in ameliorating the symptoms of fibromyalgia.
- Quanterix finds link between heart attack-induced hypoxia and suspected alzheimer’s pathway
Quanterix Corp., enabling a new generation of diagnostics based on revolutionary Single Molecule Array (SiMoA) technology, announced that significant elevations in blood levels of amyloid beta (Abeta) 42 peptide, a component of the plaques that are a hallmark of Alzheimer’s disease, were detected in patients who experienced hypoxia (inadequate supply of oxygen to the brain) following cardiac arrest.
- Allen Institute scores first comprehensive gene map of the human brain
The Allen Institute for Brain Science released the world’s first anatomically and genomically comprehensive human brain map, a previously unthinkable feat made possible through leading-edge technology and more than four years of rigorous studies and documentation. The unprecedented mappings are the foundation for the Allen Human Brain Atlas, an online public resource developed to advance the Institute’s goal to accelerate understanding of how the human brain works and fuel new discovery among the global research community.
- Bone Solutions plans study of OsteoCrete for spinal fusion indication
Bone Solutions Inc., a privately held medical device company, announced the completion of a pilot study indicating that its OsteoCrete product may be the first bone void filler (BVF) to be successfully used as a fusion-facilitator in a rabbit posterolateral lumbar spine model. OsteoCrete is already FDA-cleared as a bone void filler (BVF). The Company also announced that it intends to commence production of OsteoCrete early in the fourth quarter of this year.